Michael Burry’s Latest Buys Include a 6.66% Yielding Pharma Giant and an Oil Stock Up 46% This Year. Here Is Why

Pfizer (NYSE:PFE) astatine $25.75, Molina Healthcare (NYSE:MOH) astatine $186.80, and Halliburton (NYSE:HAL) astatine $41.29 commercialized astatine defensive, cash-generative valuations. Michael Burry purchased these shares for their existent net and borderline stability, and with ostentation inactive pressuring margins crossed the market, names that make cash, clasp pricing power, and commercialized astatine sober multiples transportation a structural edge.

Each of these companies sits successful a antiaircraft country of its sector. Pfizer is simply a low-beta pharma elephantine lapping the COVID cliff. Molina is simply a Medicaid-focused managed attraction relation moving done a self-described trough year. Halliburton is an oilfield services person leveraged to a crisp betterment successful crude prices.

Pfizer: A 6.66% Yield and a Forward Multiple That Smells Like a Rebound

Pfizer trades astatine a guardant P/E of 9 against a trailing P/E of 20, with the spread reflecting expert expectations for net enlargement arsenic the COVID resistance fades. The 6.66% dividend output is uncommon among large-cap pharma, and the 0.305 beta puts Pfizer among the slightest volatile names successful the S&P 500.

The expert who called NVIDIA successful 2010 conscionable named his apical 10 stocks and Halliburton wasn't 1 of them. Get them present FREE.

The non-COVID portfolio grew 9% operationally successful Q4 2025, and absorption has flagged astir 20 pivotal proceedings starts ahead, including obesity assets from the Metsera acquisition. The expert people of $29.11 implies meaningful upside from here, and shares are up 25.15% implicit the past year. Targets are not guarantees, but 11 of 29 covering analysts complaint the banal Buy oregon Strong Buy, with lone 3 astatine Sell oregon Strong Sell.

Molina Healthcare: Buying the Trough

Molina cratered aft Q4 2025, erstwhile adjusted EPS came successful astatine a $2.75 nonaccomplishment against a $0.50 consensus. CEO Joseph Zubretsky has since framed 2026 arsenic "a trough twelvemonth for Medicaid manufacture margins", with embedded net exceeding $11.00 per stock targeted for 2027 done 2029 arsenic caller contracts mature.

The banal has already rallied 26.64% successful the past period arsenic buyers look past the trough. The expert people sits astatine $182.25, astir adjacent with the existent price, meaning upside comes from net betterment alternatively than aggregate expansion. With a 0.848 beta and vulnerability to non-discretionary authorities healthcare spending, Molina is simply a contrarian ostentation hedge.